Newsbenzinga
Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know
· Published
Article summary
Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
An excerpt from the original article.
Comments —
Loading comments…